Technical Analysis for NOVN - Novan, Inc.

Grade Last Price % Change Price Change
D 1.19 -1.65% -0.02
NOVN closed down 1.65 percent on Thursday, April 15, 2021, on 41 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical NOVN trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -1.65%
Stochastic Reached Oversold Weakness -1.65%
Wide Bands Range Expansion -1.65%
Older End-of-Day Signals for NOVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
Rose Above Lower Bollinger Band about 22 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Novan, Inc. Description

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Infectious Diseases Stage Pharmaceutical Dermatology Acne Chemical Entities Skin Diseases Fungal Infection Acne Vulgaris Fungal Infections Product Candidates Cutaneous Conditions Genital Wart Inflammatory Skin Diseases Treatment Of Inflammatory Skin Diseases

Is NOVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.59
52 Week Low 0.3011
Average Volume 10,447,986
200-Day Moving Average 0.89
50-Day Moving Average 1.63
20-Day Moving Average 1.48
10-Day Moving Average 1.42
Average True Range 0.15
ADX 17.31
+DI 13.72
-DI 28.44
Chandelier Exit (Long, 3 ATRs ) 1.34
Chandelier Exit (Short, 3 ATRs ) 1.61
Upper Bollinger Band 1.74
Lower Bollinger Band 1.22
Percent B (%b) -0.06
BandWidth 34.91
MACD Line -0.08
MACD Signal Line -0.05
MACD Histogram -0.0351
Fundamentals Value
Market Cap 163.59 Million
Num Shares 137 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -1.24
Price-to-Sales 6.33
Price-to-Book 10.61
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.36
Resistance 3 (R3) 1.37 1.32 1.33
Resistance 2 (R2) 1.32 1.28 1.32 1.32
Resistance 1 (R1) 1.26 1.25 1.23 1.25 1.31
Pivot Point 1.21 1.21 1.19 1.20 1.21
Support 1 (S1) 1.14 1.16 1.12 1.13 1.07
Support 2 (S2) 1.09 1.13 1.09 1.06
Support 3 (S3) 1.03 1.09 1.05
Support 4 (S4) 1.02